SS-31

SS-31 is an alternating aromatic-cationic tetrapeptide that crosses membranes independently of potential gradients and accumulates roughly a thousand-fold in the inner mitochondrial membrane. There it binds cardiolipin, the signature phospholipid of that membrane, and stabilises the interaction between cardiolipin and cytochrome c. The practical consequences are better-organised cristae, more efficient electron transport, higher ATP production per unit oxygen consumed, and less reactive oxygen species leaking from the chain. It is not an antioxidant in the scavenging sense — it reduces ROS generation upstream rather than mopping it up. Approval was granted in Barth syndrome, a genetic cardiolipin remodelling disorder, which is the cleanest possible proof-of-mechanism; results in the broader primary mitochondrial myopathy population were more equivocal.

Targets: Cardiolipin, Cytochrome c, Inner mitochondrial membrane cristae, Electron transport chain complexes I-IV

• · 40 mg once daily for patients 30 kg and above; reduced to 20 mg daily in severe renal impairment (eGFR under 30 and not on dialysis).
• · Grey-market protocols run far below the approved 40 mg dose, largely on cost grounds. There is no evidence that 5-10 mg reproduces the label effect — this is a community convention, not a validated dose.

Work out your exact syringe units →

• very commonInjection-site reactions — redness, itching, induration— The dominant adverse event in every trial; site rotation is not optional at daily dosing.
• commonHeadache
• commonNausea or diarrhoea
• uncommonDizziness
• rareHypersensitivity reaction— Stop and seek care for spreading rash, wheeze or facial swelling.

• Known hypersensitivity to elamipretide or to benzyl alcohol in the commercial formulation.
• Severe renal impairment requires dose reduction rather than avoidance — do not run the full 40 mg with eGFR under 30.

• synergynad-plus — Common pairing — one targets membrane structure, the other cofactor availability; no trial has tested the combination.
• synergymots-c — Frequently stacked as a structure-plus-signalling mitochondrial pair.

• · Renal function before starting and periodically, because of the eGFR-based dose adjustment.
• · Injection-site inspection at every dose.
• · Functional endpoints — six-minute walk, grip strength, or whatever deficit you are actually trying to move.

FDA-approved as Forzinity for Barth syndrome (accelerated approval, September 2025). All other use is off-label, and research-grade SS-31 is sold as a research chemical.

• FORZINITY (elamipretide) US prescribing information, 2025 (label)
• Reid Thompson et al., TAZPOWER trial of elamipretide in Barth syndrome (trial)
• Karaa et al., MMPOWER-3 trial of elamipretide in primary mitochondrial myopathy (trial)
• Szeto, review of cardiolipin-targeted peptides and mitochondrial protection (review)

SS-31 works by being an unusual physical object rather than by binding a receptor. The alternating aromatic-cationic architecture — two cationic residues, two aromatic residues, arranged so that charge and hydrophobicity alternate — allows it to partition into lipid bilayers without needing a membrane potential to pull it in, which is what distinguishes it from triphenylphosphonium-tagged mitochondrial agents that depend on the potential gradient and therefore fail precisely in the depolarised mitochondria you most want to fix. Once inside it concentrates in the inner mitochondrial membrane, reportedly on the order of a thousand-fold over cytosolic concentration, where it associates with cardiolipin, the four-tailed phospholipid unique to that membrane. The 2020 Journal of Biological Chemistry work from Mitchell and colleagues refined the mechanism significantly: SS-31 partitions into the interfacial region of the bilayer with affinity that tracks membrane surface charge, and it modulates surface electrostatics rather than acting as a simple stoichiometric cardiolipin ligand. The functional consequences follow from that. Cardiolipin normally holds cytochrome c in place and maintains cristae curvature; when cardiolipin is abnormal or peroxidised, cytochrome c gains peroxidase activity, cristae flatten, and electron transport becomes leaky. SS-31 stabilises the cardiolipin-cytochrome c interaction, restores cristae organisation, and increases ATP produced per unit oxygen consumed. Separately, work in aged cardiomyocytes showed SS-31 associates with ANT1 and the ATP synthasome and reduces the elevated proton leak that characterises the aged heart. Critically, SS-31 is not a free-radical scavenger — it reduces reactive oxygen species by making the chain leak less, upstream, rather than by mopping up what has already leaked. That distinction matters because it means the effect should be largest exactly where electron transport is most dysfunctional, which is why Barth syndrome, a genetic disorder of cardiolipin remodelling, was the indication that finally worked when the broader mitochondrial myopathy population did not.

The single biggest error is assuming the approval means the drug works for what you want. It is approved for one thing — improving muscle strength in Barth syndrome, a genetic cardiolipin remodelling disorder, at 30 kg and above — under accelerated approval on an intermediate endpoint, and its own randomised primary endpoints in that trial were not met. In the much larger population of people with genuine primary mitochondrial myopathy, the phase 3 failed. There is no trial in healthy ageing that has reported efficacy; the only registered study in that population is a 30-person safety trial that is still recruiting. The second error is the dose. Grey-market longevity protocols run 5-10 mg daily against an approved dose of 40 mg daily, purely because 40 mg of research peptide is expensive. Nothing suggests 5 mg reproduces the label effect, and the label effect itself took months to years to appear. If you are going to run a quarter of the dose for a twelfth of the duration you should be honest that you are running a placebo with a good story. The third is renal: people with reduced eGFR who never check it get 125% higher parent exposure and 640% higher M2 metabolite exposure, and the label response to that is to halve the dose. The fourth is injection sites — 100% of trial patients had local reactions, this is daily dosing, and people who do not rotate rigorously end up with induration that ends the protocol. The fifth is the eosinophilia at around 90 days, which is documented and transient, and which people either panic about or ignore when it does not resolve.

• Cardiolipin in the inner mitochondrial membrane — Binding is to cardiolipin-containing bilayers rather than to a discrete site; affinity tracks membrane surface charge. Published work characterises partition behaviour rather than a single Kd, and analogue comparisons show large differences in equilibrium binding across the SS-peptide series.

  Stabilises cardiolipin-cytochrome c association, preserves cristae curvature, improves electron transport chain efficiency and reduces electron leak. This is the primary and defining interaction.

• Cytochrome c — Indirect — via the cardiolipin-cytochrome c complex rather than direct peptide-protein binding.

  Prevents cardiolipin-induced peroxidase activity of cytochrome c, which is a key step in mitochondrial oxidative damage and in apoptosis initiation.

• Adenine nucleotide translocase 1 (ANT1) and the ATP synthasome — Association demonstrated; no affinity constant published.

  Reduces the elevated mitochondrial proton leak characteristic of aged cardiomyocytes, which is the most directly ageing-relevant finding for the compound.

• Inner mitochondrial membrane electrostatic surface — Partitioning into the interfacial region with affinity proportional to surface charge.

  Modulation of membrane surface potential, which the 2020 JBC work argues is a core component of the mechanism rather than a side effect of cardiolipin binding.

• TAZPOWER (NCT03098797) — elamipretide in Barth syndrome Phase 2/3 · n=12 · 28 weeks · 2021

  Six-minute walk test distance and Barth Syndrome Symptom Assessment Total Fatigue Score in the randomised double-blind crossover phase. Neither primary endpoint showed superiority of elamipretide over placebo. The accelerated approval rests instead on knee extensor muscle strength by handheld dynamometry, an intermediate clinical endpoint, observed in the open-label extension.

• TAZPOWER 168-week open-label extension Open-label extension · n=10 · 168 weeks · 2024

  Long-term efficacy and safety at 40 mg subcutaneously daily. Cumulative six-minute walk improvement of 96.1 m at week 168 (p = 0.003), fatigue scores below baseline at all timepoints, improving 3D left ventricular volumes, and improved MLCL/CL cardiolipin ratios correlating with clinical outcome. Eight of ten participants completed week 168.

• MMPOWER-3 (NCT03323749) — elamipretide in primary mitochondrial myopathy Phase 3 · n=218 · 24 weeks · 2023

  Six-minute walk test distance and Primary Mitochondrial Myopathy Symptom Assessment total fatigue score. The trial did not meet its primary endpoints in the overall genotypically diverse population — this is the largest and most rigorous test elamipretide has faced and it failed it.

• MMPOWER (NCT02367014) — randomised dose-escalation in primary mitochondrial myopathy Phase 1/2 · n=36 · 1 weeks · 2018

  Change in six-minute walk distance after 5 days of intravenous elamipretide at 0.01, 0.1 and 0.25 mg/kg/h. The highest dose group walked 64.5 m further versus 20.4 m for placebo (p = 0.053); the adjusted analysis gave 51.2 m versus 3.0 m (p = 0.0297).

• MMPOWER-2 (NCT02805790) — randomised crossover in primary mitochondrial myopathy Phase 2 · n=30 · 4 weeks · 2020

  Six-minute walk test distance by visit. Participants reported reduced fatigue on elamipretide; the walk-distance result did not carry through to the phase 3.

• PROGRESS-HF (NCT02914665) — elamipretide in hospitalised heart failure Phase 2 · n=308 · 2 weeks · 2019

  Change in NT-proBNP between baseline and day 8 or early discharge.

• ReCLAIM-2 (NCT03891875) — elamipretide in dry age-related macular degeneration Phase 2 · n=176 · 48 weeks · 2023

  Change in best-corrected visual acuity and change in geographic atrophy area.

• ReNEW (NCT06373731) — subcutaneous elamipretide in dry age-related macular degeneration Phase 3 · n=313 · 48 weeks · 2026

  Rate of change of photoreceptor loss at week 48. Active, not recruiting as of this writing.

• Study of healthy aging and physical function with elamipretide (NCT07275424) Phase 2 · n=30 · 2026

  Safety and tolerability of subcutaneous elamipretide injections in healthy ageing — adverse events and completion rates. Recruiting as of this writing. This is the first registered trial that actually addresses the population buying SS-31 off-label, and it is a safety study, not an efficacy study.

Hours: peak plasma concentration at 30-60 minutes, steady state within about two days given the short half-life and minimal accumulation. That tells you nothing about effect, because tissue mitochondrial retention outlasts plasma exposure by a wide margin — this is why once-daily dosing works for a drug with a 2-4 hour plasma half-life. Weeks one to four: injection-site reactions establish themselves; this is what you will actually notice. Some off-label users report subjective energy change inside two weeks, which is not supported by anything in the trial data. Around day 90: transient eosinophilia peaks. Months three to six: this is the earliest window in which the trials saw functional muscle change, and even then it was modest. Week 168 in the Barth extension: 96.1 m cumulative six-minute walk gain and 63 newtons of knee extensor strength. That is the real timescale of this drug — years, not weeks. Anyone reporting a dramatic two-week transformation is reporting something other than elamipretide pharmacology.

SS-31 plus NAD+ or an oral NAD+ precursor is the most common longevity stack and the most mechanistically sensible one in this class: SS-31 fixes the machine, NAD+ supplies the currency it runs on, and they do not overlap at any node. No trial has tested the combination. SS-31 plus MOTS-c is the structure-plus-signalling pair, equally coherent and equally untested. The interaction that actually matters is not with another peptide at all — it is with anything that loads the kidney, because elimination is essentially 100% renal. If you are running SS-31 alongside high-dose NSAIDs, a contrast study, dehydration from a hard cut, or any nephrotoxic agent, your exposure goes up and the inactive metabolites go up much more steeply than the parent. Check renal function rather than assuming. There is no CYP-mediated interaction surface, so oral medications are broadly unaffected. Note also that the commercial formulation contains benzyl alcohol as preservative — relevant if you are stacking multiple preserved injectables and accumulating benzyl alcohol exposure, and an absolute problem in neonates.

SS-31 is the only compound in this entire class with an FDA approval, a published label, real human pharmacokinetics and phase 3 data. That makes it the strongest member of the class by a wide margin and it is worth stating plainly. But the comparison that matters is internal: within SS-31's own evidence base, the strong result is a 12-person trial in a rare genetic cardiolipin disorder, and the weak result is a 218-person phase 3 in the broader mitochondrial disease population that failed. Against MOTS-c and humanin, there is no contest on evidence quality. Against NAD+ and its precursors: NAD+ has more human trials but almost all of them show you can raise the biomarker without moving a clinical endpoint, whereas SS-31 has moved clinical endpoints in one narrow population. Against coenzyme Q10 and other mitochondrial supplements: SS-31 has an actual defined molecular mechanism, membrane pharmacology and a regulatory dossier, which CoQ10 supplementation does not. Against doing nothing, for a healthy person seeking anti-ageing benefit: unknown, and that is the honest answer. The registered healthy-ageing trial is a safety study that has not reported.

$150–$900/month. Not verified against live pricing this session, and the spread here is enormous and structural. Research-grade lyophilised SS-31 run at community doses of 5-10 mg daily lands at the low end. Running the actual approved 40 mg daily dose means 1.2 g per month, which puts research-grade cost near the top of this range or above it. The commercial product FORZINITY is an orphan drug priced accordingly — its list price is far outside this range and is not what grey-market users pay. Any figure you see quoted should be checked against whether it assumes label dose or community dose, because they differ eightfold.

• ?Plasma half-life: the Core figure of 2-4 hours is consistent with the label's Tmax and near-complete 48-hour urinary recovery, but I did not resolve an explicitly published terminal half-life number in this session.
• ?Volume of distribution is given in the label as approximately 0.5 L/kg; the 35 L figure here is that value scaled to a 70 kg adult and is a derived number, not a directly reported one.
• ?Whether SS-31 crosses the blood-brain barrier is not stated in the label and I could not resolve it. Given the compound's use in retinal and neurological indications by local or systemic routes, this is a real open question.
• ?Time to steady state is inferred from short half-life plus the label's statement of minimal accumulation, not directly reported as a number.
• ?There is no efficacy evidence at all for the 5-10 mg community dose. Whether it does anything is genuinely unknown.
• ?The thousand-fold inner-membrane accumulation figure is widely cited from the older Szeto laboratory work; I did not resolve the primary source for that specific number in this session, so treat the magnitude as approximate.
• ?No published trial has tested SS-31 in healthy ageing adults for efficacy. NCT07275424 is a safety study and had not reported at the time of writing.
• ?Cost figures are estimates and were not verified against live vendor or pharmacy pricing.
• ?Whether the eosinophilia represents a benign pharmacodynamic effect or a low-grade immune response with long-term implications is not resolved in the label.
• ?Trial identities, phases and enrolment numbers were verified against ClinicalTrials.gov and the published abstracts. Some durationWeeks values (MMPOWER-3 at 24 weeks, MMPOWER-2 at 4 weeks, PROGRESS-HF at 2 weeks, ReCLAIM-2 at 48 weeks) are the commonly reported figures rather than values I resolved directly in this session — TAZPOWER's 28-week randomised phase, its 168-week extension and ReNEW's week-48 endpoint were confirmed.

• FORZINITY (elamipretide hydrochloride) injection, for subcutaneous use — US prescribing information Stealth BioTherapeutics Inc., DailyMed / FDA label, 2025

  The source of every pharmacokinetic number in this record: 0.5-1 h Tmax, ~92% subcutaneous bioavailability, ~0.5 L/kg volume of distribution, ~39% protein binding, C-terminal degradation to inactive M1 and M2, ~100% urinary recovery in 48 h, renal impairment exposure increases, minimal accumulation, and the eosinophilia observation. 40 mg once daily for patients at least 30 kg; 280 mg/3.5 mL (80 mg/mL) solution.

• Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ, Genetics in Medicine, 2024 · PMID 38602181

  The long-term data that underpins the approval. 96.1 m cumulative 6MWT gain at week 168, improving cardiolipin biomarkers, injection-site reactions as the dominant adverse event.

• Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial Karaa A, Bertini E, Carelli V, et al., Neurology, 2023 · PMID 37268435

  The negative phase 3. Read this one before you buy SS-31 for general mitochondrial ageing — 218 patients with genuine mitochondrial disease, and it did not beat placebo on its primary endpoints.

• Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial Karaa A, Bertini E, Carelli V, et al., Orphanet Journal of Rare Diseases, 2024 · PMID 39574155

  The post hoc genotype analysis and exposure-response work explaining why a genotypically mixed population may have diluted a real effect in specific subgroups. Post hoc, so hypothesis-generating rather than conclusive.

• Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH, Neurology, 2018 · PMID 29500292

  The dose-ranging study — 36 adults, three intravenous dose levels over 5 days, 6MWT primary endpoint. The dose-response signal that launched the whole clinical programme.

• The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action Mitchell W, Ng EA, Tamucci JD, et al., Journal of Biological Chemistry, 2020 · PMID 32273339

  The best mechanistic paper on how SS-31 actually interacts with membranes — partitioning into the interfacial region with affinity related to surface charge, rather than acting as a simple cardiolipin ligand.

• Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds Mitchell W, Tamucci JD, Ng EL, et al., eLife, 2022 · PMID 35913044

  Compares SS-31 against sibling analogues and shows they all bind cardiolipin-containing membranes but with significantly different equilibrium behaviour — useful context for anyone assuming grey-market 'SS-31-like' peptides are equivalent.

• Reduction of elevated proton leak rejuvenates mitochondria in the aged cardiomyocyte Zhang H, Alder NN, Wang W, Szeto H, Marcinek DJ, Rabinovitch PS, eLife, 2020 · PMID 33319746

  The most directly ageing-relevant mechanistic paper — SS-31 associating with ANT1 and the ATP synthasome and reducing the elevated proton leak of the aged heart. This is the study the anti-ageing use case is actually built on, and it is in cardiomyocytes, not people.

• Elamipretide: a review of its structure, mechanism of action, and therapeutic potential Tung C, Varzideh F, Farroni E, et al., International Journal of Molecular Sciences, 2025 · PMID 39940712

  Current review covering PROGRESS-HF, TAZPOWER, MMPOWER-3 and ReCLAIM in one place. The fastest way to see the full clinical programme including the trials that did not work.

• Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide Daubert MA, Yow E, Dunn G, et al., Circulation: Heart Failure, 2017 · PMID 29217757

  The heart failure programme. Relevant because cardiovascular benefit is one of the reasons people buy SS-31 off-label, and the cardiology results have been mixed rather than positive.

• Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome Hornby B, Thompson WR, Almuqbil M, Manuel R, Abbruscato A, Carr J, Vernon HJ, Orphanet Journal of Rare Diseases, 2022 · PMID 36056411

  The external natural-history comparison used to support efficacy given the tiny randomised sample. Worth knowing this is part of the evidence package, because it is a weaker design than a randomised comparison.